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OBJECTIVES We investigated associations between single nucleotide polymorphisms (SNPs) in the hepatic
lipase promoter, levels of high-density lipoprotein (HDL), and risk of ischemic heart disease
(IHD). Our primary hypothesis was that these SNPs associate with IHD after adjustment for
HDL levels.
BACKGROUND Hepatic lipase influences HDL metabolism, and may thus affect reverse cholesterol transport
and consequently risk of IHD.
METHODS We genotyped 9,121 white subjects aged 20 to 93 years from the Copenhagen City Heart
Study, 456 of whom had incident IHD, as well as 921 Danish patients with IHD for the
216, 480, and 729 SNPs in the hepatic lipase promoter.
RESULTS Frequencies of wild-type, triple heterozygotes, and triple mutation homozygotes in the
general population were 61%, 33%, and 5%, respectively. Compared with wild-type, HDL
cholesterol levels were 4% (0.06 mmol/l) and 10% (0.15 mmol/l) higher in heterozygotes and
mutation homozygotes; the equivalent values for apolipoprotein A1 were 3% and 7% higher.
In prospective and case-control studies, mutation homozygotes versus wild-type had relative
risk (RR) and odds ratio (OR) for IHD of 1.5 (95% confidence interval [CI]: 1.0 to 2.2) and
1.4 (CI: 1.1 to 1.9) when adjusted for age, gender, and HDL cholesterol. In individuals with
the 43 apolipoprotein E genotype, RR and OR for IHD in mutation homozygotes versus
wild-type was 2.9 (CI: 1.5 to 5.6) and 2.0 (CI: 1.2 to 3.2).
CONCLUSIONS Hepatic lipase promoter SNPs are associated with increased HDL cholesterol and, paradox-
ically, an increased risk of IHD after adjustment for HDL cholesterol, and particularly in
individuals with apolipoprotein E 43 genotype. Implications are that increased HDL levels
may in certain situations be not protective, but rather associated with increased IHD
risk. (J Am Coll Cardiol 2003;41:1972–82) © 2003 by the American College of Cardiology
Foundation
Elevated high-density lipoprotein (HDL) cholesterol is
associated with reduced risk of ischemic heart disease
(IHD) in epidemiological studies (1). This could be because
high HDL levels are associated with reduced levels of
triglyceride-rich lipoproteins and/or small, dense low-
See page 1990
density lipoprotein (LDL), both of which may cause ath-
erosclerosis (1,2). Alternatively, high HDL levels may mark
fully functional reverse cholesterol transport (1)—i.e., trans-
port of excess cholesterol from the arterial intima back to
the liver for excretion. Dysfunctional reverse cholesterol
transport due to mutations in cholesteryl ester transfer
protein may, however, also lead to elevated HDL levels, but
paradoxically to increased risk of IHD (3).
Hepatic lipase hydrolyzes phospholipids and triglycerides in
HDL and may influence reverse cholesterol transport (4). Four
linked single nucleotide polymorphisms (SNPs) in the hepatic
lipase promoter (5,6) (Table 1) associate with decreased he-
patic lipase activity (7–12). These promoter SNPs may also
influence levels of lipids and lipoproteins (5,7,9,10,13–15), and
consequently affect risk of IHD. We hypothesized that dys-
functional hepatic lipase may associate with elevated HDL
levels and paradoxical increased IHD risk, exactly as found for
dysfunctional cholesteryl ester transfer protein (3,16).
Genotyping over 10,000 individuals and using cross-
sectional, prospective, and case-control designs, we investi-
gated associations between hepatic lipase promoter SNPs
and levels of lipids and lipoproteins, and risk of IHD. Our
primary hypothesis was that hepatic lipase SNPs are asso-
ciated with risk of IHD, particularly after adjustment for
HDL cholesterol levels, as in our two former studies on
cholesteryl ester transfer protein SNPs (16,17). Because the
apolipoprotein E polymorphism has profound influence on
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lipids, lipoproteins, and IHD risk (18), analyses in this study
were stratified not only for gender but also for the three
common apolipoprotein E genotypes, 32, 33, and 43.
METHODS
For the cross-sectional study we included all genotyped
individuals except 29 outliers with triglycerides 10
mmol/l. For the prospective and case-control studies, only
those subjects with the three most common genotypes
(Table 2) who did not receive lipid-lowering medication
were included.
Subjects. We studied lipids, lipoproteins, and apolipopro-
teins cross-sectionally in 5,047 women and 4,074 men from
the Copenhagen City Heart Study (third examination, 1991
to 1994) (16–18). This is an age-stratified representative
sample of the adult Danish general population.
The Copenhagen City Heart Study was also studied
prospectively from 1991 through 1994 until the end of
1998: 205 women and 251 men with incident IHD were
diagnosed by experienced cardiologists based on myocardial
infarction (MI) and/or angina pectoris (WHO International
Classification of Diseases, 8th ed. pp. 410–14), by reviewing
the Danish National Hospital Discharge Register, the
Danish National Register of Causes of Deaths, and medical
records from hospitals and general practitioners (16–18).
Participants with prevalent IHD diagnosed before exami-
nation in 1991 through 1994 were excluded.
For the case-control study to gain more statistical power,
we pooled incident and prevalent IHD cases from the
Copenhagen City Heart Study with other IHD cases
referred for coronary angiography between 1991 and 1993,
which added 383 women and 902 men with IHD to the
incident cases. In cases referred for coronary angiography,
IHD was diagnosed by experienced cardiologists based on
stable angina pectoris plus at least one of the following:
severe stenosis on coronary angiography (70% stenosis of
at least one coronary artery or 50% stenosis of the left
main coronary artery), previous MI, or a positive exercise
electrocardiographic (ECG) test (16–18).
In all groups, more than 99% were white subjects of
Danish descent. Danish ethical committees (No.
100.2039/91 and KA93125) approved the studies.
Both measurements and detection of conventional car-
diovascular risk factors were as described previously
(16–18). Colorimetric and turbidimetric assays were used to
measure plasma levels of total cholesterol, HDL cholesterol,
triglycerides, apolipoprotein AI, apolipoprotein B (all by
Boehringer Mannheim, Mannheim, Germany), and li-
poprotein(a) (DAKO A/S, Glostrup, Denmark). Non-
HDL cholesterol was total cholesterol minus HDL choles-
terol, whereas LDL cholesterol was total cholesterol minus
both HDL cholesterol and very low density cholesterol
(estimated as 0.45  triglycerides).
DNA analyses. The SNPs in the hepatic lipase promoter at
positions 729, 480, and 216 (Table 1) were detected by
polymerase chain reaction (PCR) followed by digestion with
restriction enzymes. The PCR was performed using the sense
primer 5-TCCTGGCCAGAAATCTCTTCT-3 and the
anti-sense primer 5-GACTTGTGTCCATTTCTCCGT-
3. A PCR product aliquot was digested with DraI recognizing
the 216A mutation and an internal control site (216G:
756bp, 194bp; 216A: 640bp, 194bp, 116bp). A second
aliquot was digested with NlaIII recognizing the 729G and
480T mutations and an internal control site (729A/
480C: 822bp, 128bp; 729A/480T: 440bp, 382bp,
128bp; 729G/480C: 690bp, 132bp, 128bp; 729G/
480T: 440bp, 250bp, 132bp, 128bp). The DNA fragments
were analyzed by electrophoresis in a 2% agarose gel. An assay
developed for the 676 SNP necessitated polyacrylamide gel
electrophoresis for sufficient resolution of DNA band sizes and
was avoided due to time and toxicity considerations.
We sequenced parts of the hepatic lipase promoter in 157
subjects and confirmed the 11 different genotypes observed,
as well as linkage disequilibrium between the three studied
SNPs and the T(676)3C SNP (5). One subject appar-
ently with a mutation at position 729 had instead a
C(764)3T mutation. This generates another NlaIII site,
explaining the initial result. We also discovered two other
mutations not previously reported: G(568)3T (39 het-
erozygotes, 3 homozygotes) and G(558)3A (9 heterozy-
gotes, 1 homozygote), which appeared primarily in individuals
with genotypes found in1% of the general population (Table
2). Because of the frequency and distribution of these SNPs,
they do not invalidate the overall results in the present study
and do not contradict previous results (5,7–15).
Apolipoprotein E genotyping was performed as previ-
ously described (16).
Statistical analyses. Statistical analyses were performed
using SPSS. A p value 0.05 on a two-sided test was
significant. Except where explicitly stated, correction for
multiple comparisons was not performed. A priori we
stratified by gender; however, to increase the statistical
power when analyzing risk of IHD, we also examined the
two genders combined. We also a priori stratified for
apolipoprotein E genotype, because this polymorphism has
profound influence on lipids, lipoproteins, and IHD (18).
Table 1. Single Nucleotide Polymorphisms in the Hepatic
Lipase Promoter
Position 729 676 480 216
Base substitution A3G T3C C3T G3A
Alternative position (5) 763 710 514 250
Abbreviations and Acronyms
ANOVA  analysis of variance
HDL  high-density lipoprotein
IHD  ischemic heart disease
LDL  low-density lipoprotein
PCR  polymerase chain reaction
SNPs  single nucleotide polymorphisms
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We used the Kruskal-Wallis analysis of variance
(ANOVA) with Mann-Whitney U test for post hoc two-
genotype comparisons. Analysis of covariance tested for
multiplicative interaction among genotype and HDL cho-
lesterol, apolipoprotein AI, triglycerides, non-HDL choles-
terol, apolipoprotein B, lipoprotein(a), cholesteryl ester
transfer genotype (16,17), apolipoprotein E genotype (18),
body-mass index, waist/hip ratio, glucose, alcohol consump-
tion, systolic blood pressure, diastolic blood pressure, age,
hypertension, use of diuretics, diabetes mellitus, IHD,
smoking, physical activity, menopause (women), and hor-
monal replacement therapy (women) in the prediction of
HDL cholesterol, apolipoprotein AI, triglycerides, and
non-HDL cholesterol. Triglycerides were log10-transformed.
Cox and unconditional logistic regression examined as-
sociations between genotype and IHD. Regression analyses
were made 1) adjusted for age and gender, and 2) adjusted
for age, gender, and HDL cholesterol (in quintiles); when
HDL is adjusted for, the strong inverse association between
HDL and IHD risk cannot mask an association between
these SNPs and IHD. Multiplicative interactions between
genotype and gender and other cardiovascular risk factors on
IHD risk were examined.
RESULTS
Characteristics, levels of lipids and lipoproteins, and apoli-
poprotein E genotype frequencies have been presented
previously (16–18).
Genotype frequencies. Frequencies of hepatic lipase pro-
moter genotypes in the general population are given in
Table 2. It has previously been reported that the 729G,
480T, and 216A variants are in linkage disequilibrium
(5), which was confirmed in our sample: noncarriers (wild-
type), heterozygotes, and mutation homozygotes for this
haplotype constituted 61%, 33%, and 5%, respectively, of all
genotype combinations. The remaining 1% was distributed
between eight other genotype combinations, all hitherto
undescribed. Allele frequencies of 729G, 480T, and
216A were 0.218, 0.212, and 0.218, respectively. Geno-
type distributions did not differ significantly from Hardy-
Weinberg equilibrium (chi-square, p  0.5 for each SNP).
Lipids and lipoproteins. Relative to wild-type, levels of
HDL cholesterol were 4% (0.07 mmol/l) and 3% (0.04
mmol/l) higher in triple heterozygous women and men and
10% (0.17 mmol/l) and 9% (0.12 mmol/l) higher in triple
mutation homozygous women and men, respectively (Fig.
1, Table 2); the equivalent values for apolipoprotein AI (the
main protein constituent of HDL) were 3% and 2% for
heterozygous and 7% and 6% for mutation homozygous
women and men, respectively (all ANOVAs: p  0.001).
No significant differences existed in levels of triglycerides,
non-HDL cholesterol, apolipoprotein B, and lipoprotein(a)
among the three major genotypes (Fig. 1, latter two not
shown). Additionally, no difference was seen in LDL
cholesterol levels among the three genotypes, in the
Table 2. Lipids and Lipoproteins by Hepatic Lipase Promoter Single Nucleotide Polymorphisms in Cross-Sectional Study of the
General Population
Genotype
HDL
Cholesterol (mmol/l)
Apolipoprotein AI
(mg/dl)
Triglycerides
(mmol/l)
Non-HDL Cholesterol
(mmol/l)
Code 729 480 216 n % Mean (95% CI)
Women
Wild A/A C/C G/G 3,072 60.9 1.69 (1.68–1.71) 149 (148–150) 1.67 (1.64–1.70) 4.56 (4.52–4.61)
Hetero A/G C/T G/A 1,692 33.5 1.76 (1.74–1.79) 153 (152–155) 1.69 (1.64–1.74) 4.57 (4.51–4.64)
Homo G/G T/T A/A 213 4.2 1.86 (1.79–1.93) 160 (156–164) 1.73 (1.61–1.85) 4.54 (4.34–4.74)
A/G C/C G/A 51 1.0 1.66 (1.52–1.80) 148 (140–156) 1.59 (1.36–1.83) 4.39 (4.00–4.78)
G/G C/T A/A 7 0.1 1.89 (1.58–2.19) 156 (144–168) 1.65 (0.89–2.40) 5.23 (3.88–6.58)
A/G C/C G/G 5 0.1 1.54 (1.05–2.03) 149 (124–174) 1.99 (0.09–3.90) 4.24 (2.67–5.81)
A/G C/T G/G 4 0.1 1.95 (1.62–2.28) 183 (163–202) 1.52 (0.74–2.30) 4.43 (2.87–5.98)
A/A C/C G/A 1 0.0 2.3 182 0.98 4.2
G/G C/C A/A 1 0.0 1.8 136 1.21 4.5
G/G C/T G/A 1 0.0 1.5 123 1.30 3.2
A/G T/T A/A 0 0.0
Men
Wild A/A C/C G/G 2,494 61.2 1.36 (1.35–1.38) 128 (128–129) 2.00 (1.95–2.05) 4.53 (4.48–4.57)
Hetero A/G C/T G/A 1,335 32.8 1.41 (1.38–1.43) 131 (130–133) 2.07 (2.00–2.14) 4.63 (4.56–4.70)
Homo G/G T/T A/A 194 4.8 1.48 (1.42–1.54) 136 (132–140) 1.98 (1.82–2.14) 4.48 (4.33–4.64)
A/G C/C G/A 36 0.9 1.41 (1.29–1.52) 133 (125–141) 1.86 (1.62–2.11) 4.98 (4.65–5.30)
G/G C/T A/A 10 0.2 1.50 (1.18–1.82) 140 (123–158) 1.80 (1.31–2.29) 3.56 (3.01–4.11)
A/G C/C G/G 4 0.1 1.48 (0.01–2.94) 132 (66–199) 2.04 (0.00–5.07) 3.40 (0.18–6.62)
A/G C/T G/G 0 0.0
A/A C/C G/A 0 0.0
G/G C/C A/A 0 0.0
G/G C/T G/A 0 0.0
A/G T/T A/A 1 0.0 2.0 168 1.65 3.2
A  adenine; C  cytosine; CI  confidence interval; G  guanine; HDL  high-density lipoprotein; Hetero  heterozygotes; Homo  homozygotes; T  thymine; Wild
 wild-type.
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general population, or among IHD patients (data not
shown).
We tested for multiplicative interaction between hepatic
lipase promoter genotype and 22 cardiovascular risk factors
(see Methods) in the prediction of HDL cholesterol,
apolipoprotein AI, triglycerides, and non-HDL cholesterol
in each gender. Among 170 interactions tested, only three
had p values 0.05. Hypertension interacted on HDL
cholesterol (p  0.04) and apolipoprotein AI (p  0.02) in
women, but not in men (p  0.62 and p  0.87).
Apolipoprotein E genotype interacted on non-HDL cho-
lesterol in men (p  0.03), but not in women (p  0.49).
However, upon stratification only irregular patterns were
found. Furthermore, when corrected for multiple compari-
sons, none of the 170 tests of multiplicative interaction were
significant.
Lipoproteins across apolipoprotein E genotypes. Levels
of HDL cholesterol and apolipoprotein AI increased from
wild-type to triple heterozygotes to triple mutation ho-
mozygotes among subjects with 33 and 43 genotypes of
both genders and in women with the 32 genotype (Fig. 2).
Levels of HDL cholesterol and apolipoprotein AI in 32/
homozygous women were 19% (0.32 mmol/l) and 15%
(22 mg/dl) above levels in 43/wild-type women. Equiva-
lent values for men were 11% (0.14 mmol/l) and 13%
(16 mg/dl), respectively.
Risk of IHD. In the prospective study, the RR for triple
mutation homozygotes versus wild-type individuals was 1.3
(confidence interval [CI] 0.9 to 2.0) after adjustment for age
and gender, and 1.5 (CI: 1.0 to 2.2) adjusting for HDL
cholesterol as well (Fig. 3). After stratification and adjust-
ment for age, gender, and HDL cholesterol, the RR of IHD
was 2.0 (CI: 1.2 to 3.5) in women and 2.9 (CI: 1.5 to 5.6)
in those with apolipoprotein 43 genotype.
In the case-control study, triple mutation homozygotes
versus wild-type individuals had an OR for IHD of 1.3 (CI:
1.0 to 1.6) after adjustment for age and gender, and 1.4 (CI:
1.1 to 1.9) after adjustment for HDL cholesterol as well
(Fig. 4). After stratification and adjustment for age, gender,
and HDL cholesterol, the OR of IHD was 1.6 (CI: 1.0 to
2.4) in women and 2.0 (CI: 1.2 to 3.2) in those with
apolipoprotein 43 genotype.
Hepatic lipase promoter genotype did not interact mul-
tiplicatively with gender, cholesterol-lowering treatment,
cholesteryl ester transfer protein genotype, apolipoprotein E
genotype, HDL cholesterol, apolipoprotein AI, triglycer-
ides, non-HDL cholesterol, apolipoprotein B, lipopro-
tein(a), body-mass index, age, hypertension, diabetes mel-
litus, smoking, menopause, or hormonal replacement
therapy in the prediction of IHD (data not shown).
DISCUSSION
We hypothesized that dysfunctional hepatic lipase may
associate with elevated HDL levels and paradoxical in-
creased IHD risk, exactly like dysfunctional cholesteryl ester
transfer protein (3,16,19). Both enzymes are important in
reverse cholesterol transport, and elevated HDL levels may
in these situations therefore mark reduced flux of cholesterol
from the arterial intima back to the liver for excretion.
Our primary hypothesis was that hepatic lipase SNPs
were associated with risk of IHD, particularly after adjust-
ment for HDL cholesterol levels, as in our two previous
studies on cholesteryl ester transfer protein SNPs (16,17).
Generally, reduced HDL levels (also associated with
triglyceride-rich lipoproteins and small dense LDL [1,2]) is
a strong predictor of IHD (1). We wanted to examine the
effect of mutation homozygosity without interference from
this association between HDL and IHD: when HDL is
adjusted for, the inverse association between HDL and
IHD risk can no longer mask a direct association between
these SNPs and increased IHD risk.
We found that hepatic lipase promoter genotype was
associated with a stepwise increase in HDL cholesterol and
apolipoprotein AI, from wild-type to heterozygotes to
mutation homozygotes. Despite this, mutation homozygos-
ity was associated with increased risk of IHD after adjust-
ment for HDL cholesterol, and particularly in apolipopro-
tein 43 individuals.
Other researchers have previously asked questions similar to
ours in much smaller studies; however, associations among
hepatic lipase promoter mutations, HDL, and IHD have never
been examined in such large studies as ours, and particularly
not by using a prospective design of the general population. In
addition, our findings, namely that these mutations are asso-
ciated with both elevated HDL and paradoxically with in-
creased risk of ischemic heart disease, are novel.
HDL cholesterol and apolipoprotein AI. The results
presented in this study demonstrate an incremental increase
in levels of both HDL cholesterol and apolipoprotein AI
from wild-type to triple heterozygotes to triple mutation
homozygotes among both women and men, not demon-
strated previously (5,7,9,10,13–15). Reduced hepatic lipase
activity associated with these mutations in the hepatic lipase
promoter (7–12) could lead to an increase in atherogenic
remnant particles; however, we did not observe differences
in levels of triglycerides and non-HDL cholesterol. Never-
theless, reduced hepatic lipase activity may very well explain
reduced HDL metabolism with consequently higher HDL
levels (1). The HDL cholesterol received from nonliver cells
may be transferred to the liver in at least two ways as part of
the reverse cholesterol transport pathway. Cholesteryl esters
may be transferred to triglyceride-rich lipoproteins by cho-
lesteryl ester transfer protein followed by liver uptake of
these lipoproteins via LDL receptors. Alternatively, HDL
particles may be processed by hepatic lipase followed by
selective uptake of HDL cholesteryl esters by liver and
steroidogenic tissues: the class B scavenger receptor SR-BI
expressed primarily in these tissues has been shown to bind
HDL with high affinity and to mediate selective uptake of
cholesteryl esters (20).
Risk of IHD. A new and important finding in the present
study is the 40% to 50% increased risk of IHD among
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individuals homozygous for hepatic lipase promoter muta-
tions relative to wild-type after adjustment for HDL cho-
lesterol. Previous studies were smaller than the present and
were not able to document this association in mutation
homozygous individuals (7,8,14,15). Results compatible
with the present study were, however, observed in two of the
studies, in heterozygous (7) and mutation homozygous (14)
individuals, respectively. In another study (8), only patients
with HDL cholesterol 1.1 mmol/l were included, essen-
tially preselecting against these SNPs. If we apply this
preselection criterion to male IHD patients in our study, we
find an OR for IHD of 0.8 for mutation homozygotes
versus wild-type. In other words, if only individuals with
low HDL levels are studied, many of those with the
mutations associated with high HDL levels (and high risk
of IHD) simply are excluded from the study.
There are data, however, that at first hand would seem to
contradict our results: in a prospective angiographic lipid-
lowering study, Zambon et al. (21) demonstrated that a
decrease in hepatic lipase activity is associated with regres-
sion of coronary artery disease. The researchers noted,
however, that response to lipid-lowering therapy was defec-
tive in those with the rarer allele (22). Other “paradoxical”
evidence suggests that a) low hepatic lipase activity (ob-
served in premenopausal women and lean individuals) is
associated with a less atherogenic lipoprotein profile and
thus possibly with lower risk of IHD, and b) high hepatic
lipase activity (in obese individuals, those with type II
diabetes, and postmenopausal women) is associated with a
more atherogenic lipoprotein profile and thus possibly with
increased risk of IHD (23–25).
We believe that the association of hepatic lipase promoter
mutations with increased risk of IHD despite higher levels
of HDL can be explained in a straightforward manner. The
hepatic lipase promoter mutations are associated with re-
duced activity of the enzyme (7–12) and owing to this,
catabolism of HDL-2 particles decreases. The higher levels
of HDL-2 cholesterol due to reduced flux through the
reverse cholesterol transport system suggest an insufficient
removal of cholesterol from the arterial intima, ultimately
Figure 1. Levels of lipids and lipoproteins in individuals from the general population who are wild-type (Wild), triple heterozygotes (Hetero), or triple
mutation homozygotes (Homo) for hepatic lipase promoter single nucleotide polymorphisms. A, C  women; B, D  men. ANOVA  analysis of
variance; post-hoc Mann-Whitney U test: *p  0.05; **p  0.01; ***p  0.001. HDL  high-density lipoprotein. Continued on next page.
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leading to increased risk of atherosclerosis and IHD (1);
HDL-2 was unfortunately not measured in the Copenha-
gen City Heart Study. In essence, higher levels of HDL
cholesterol and apolipoprotein AI may—in this particular
context—be regarded as a secondary result of reduced flux
through the reverse cholesterol transport system, whereas in
most other contexts high levels of HDL cholesterol and
apolipoprotein AI may reflect a high capacity of this
system.
Findings analogous to the present results show that
mutations in the cholesteryl ester transfer protein associated
with elevated HDL levels and reduced enzyme activity also
associate with increased risk of IHD (3,16,19), whereas
mutations in this protein associated with reduced HDL
levels and increased enzyme activity (which could mark
increased reverse cholesterol transport) associate with re-
duced risk of IHD (17).
The significant findings after adjustment for HDL cho-
lesterol that suggest an inverse relationship between hepatic
lipase levels—strongly associated with the promoter geno-
types—and risk of IHD, could also be completely indepen-
dent of reverse cholesterol transport and atheroprotective
effects of HDL. An alternative plausible explanation could
be the role of hepatic lipase in the clearance of remnant
particles and possibly the effect of increase in hepatic lipase
activity on faster clearance of these atherogenic particles,
hence association of triple mutation homozygosity with
lower hepatic lipase activity and increased levels of IHD.
Potential interaction of apolipoprotein E genotypes and
hepatic lipase variants may suggest a coordinated function in
remnant clearance and risk of IHD.
Apolipoprotein E genotype stratification. Because the
apolipoprotein E polymorphism has profound influence on
lipids, lipoproteins, and IHD risk (18), analyses in this study
were stratified for the three common apolipoprotein E
genotypes 32, 33, and 43. Our data support a model
where apolipoprotein E genotypes and hepatic lipase pro-
moter genotypes contribute independently (that is, demon-
strate additive rather than multiplicative interaction) to plasma
levels of HDL cholesterol and apolipoprotein AI, and together
they may explain 19% and 15% differences in levels of HDL
cholesterol and apolipoprotein AI, respectively.
Figure 1 Continued. E, G  women; F, H  men.
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The finding that, among individuals with the 43 geno-
type, the risk of IHD in hepatic lipase SNP homozygotes
versus wild-type was larger than in all individuals combined
suggests that apolipoprotein E variability may mask associ-
ation between hepatic lipase SNPs and risk of IHD. In
support of this concept, apolipoprotein E variants associated
with higher HDL levels associate with reduced IHD risk
(18), in contrast to the present findings for hepatic lipase.
Thus, within a group of people with the same apolipopro-
tein E genotype, the association between hepatic lipase
genotype and risk of IHD will not be masked by contra-
dictory variability from apolipoprotein E.
Figure 2. Levels of high-density lipoprotein (HDL) cholesterol and apolipoprotein AI in individuals from the general population who are wild-type (Wild),
triple heterozygotes (Hetero), or triple mutation homozygotes (Homo) for hepatic lipase promoter single nucleotide polymorphisms, stratified for
apolipoprotein E genotype. The p values are by analysis of variance within each apolipoprotein E genotype stratum; post-hoc Mann-Whitney U test. *p 
0.05; **p  0.01; ***p  0.001. A, B  women. Continued on next page.
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Study limitations. Although we observed a clear gene
dosage effect from wild-type to triple heterozygotes to triple
mutation homozygotes on levels of HDL cholesterol and
apolipoprotein AI, this was not the case for risk of IHD,
except in the subgroup of individuals with apolipoprotein E
43 genotype. There are several possible explanations for
such a discrepancy: 1) our observation of increased risk of
IHD is a chance finding; 2) absence of increased IHD risk
among triple heterozygous individuals may be a chance
event; 3) the effect on risk of IHD is recessive rather than
co-dominant; and 4) the statistical power is much less for
the end point IHD than for levels of intermediate variables
like lipoproteins.
Lack of significant associations with IHD risk in some
strata also represent a potential limitation. Interpretations of
this phenomenon include 1) that triple mutation homozy-
Figure 2 Continued. C, D  men.
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Figure 3. Risk of ischemic heart disease in prospective study analyzed by Cox regression. Results are relative risks (95% confidence interval [CI]): CI is not corrected for multiple comparisons. Individuals
on cholesterol-lowering treatment (53 subjects, 8 events) and with unknown treatment status (87 subjects, 8 events) were excluded. *No homozygotes among cases in the 32 strata. HDL  high-density
lipoprotein; IHD  ischemic heart disease.
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Figure 4. Risk of ischemic heart disease in case-control study analyzed by unconditional logistic regression. Results are odds ratios (95% confidence interval [CI]): CI is not corrected for multiple comparisons.
Individuals on cholesterol-lowering treatment (122 cases, 45 controls) and with unknown treatment status (15 cases, 79 controls) were excluded. HDL  high-density lipoprotein. 1981
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gosity versus wild-type is associated with increased risk of
IHD in women (but not in men), and in 43 carriers (but
not in those with 32 or 33); 2) that some strata like those
with 32 genotype lack statistical power; and 3) that play of
chance determines that, for example, women but not men
demonstrate significant associations.
Study implications. The present study presents new evi-
dence that common SNPs in the hepatic lipase promoter
gene result, despite a rise in HDL, in an increased risk of
IHD, particularly in the setting of apolipoprotein E 43
genotype. This finding has implications beyond the genetic
and metabolic finding, as it indicates that elevated HDL
levels may actually be associated with increased risk of IHD
in certain situations, as has previously been reported for
mutations in the cholesteryl ester transfer protein
(3,16,17,19), another important enzyme in reverse choles-
terol transport (1). Therefore, the study is of relevance to
both research scientists and clinicians.
Implications of the findings include that increased HDL
levels may in certain situations be not protective, but rather
associated with increased IHD risk, and that our assess-
ments of HDL levels do not directly measure reverse
cholesterol transport. Thus, although the average person
with high HDL levels is protected against IHD, a subgroup
of such individuals where the opposite is true may also exist.
Therefore, some patients with high HDL levels, particularly
those with manifest IHD, need both aggressive lipid-
lowering medication and other preventive measures against
atherosclerosis and IHD.
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